772 related articles for article (PubMed ID: 10637835)
1. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
[TBL] [Abstract][Full Text] [Related]
2. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
3. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
Nicoletti F; Di Marco R; Patti F; Zaccone P; L'Episcopo MR; Reggio E; Xiang M; Nicoletti A; Reggio A
Cytokine; 2000 Jun; 12(6):682-7. PubMed ID: 10843745
[TBL] [Abstract][Full Text] [Related]
4. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
5. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.
Mei FJ; Osoegawa M; Ochi H; Minohara M; Nan S; Murai H; Ishizu T; Taniwaki T; Kira J
J Neurol Sci; 2006 Jul; 246(1-2):71-7. PubMed ID: 16581087
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P
Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
[TBL] [Abstract][Full Text] [Related]
7. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
Weber F; Polak T; Günther A; Kubuschok B; Janovskaja J; Bitsch A; Poser S; Rieckmann P
Ann Neurol; 1998 Jul; 44(1):27-34. PubMed ID: 9667590
[TBL] [Abstract][Full Text] [Related]
8. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses.
Scheurich P; Thoma B; Ucer U; Pfizenmaier K
J Immunol; 1987 Mar; 138(6):1786-90. PubMed ID: 3029221
[TBL] [Abstract][Full Text] [Related]
9. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha.
Albanesi C; Cavani A; Girolomoni G
J Immunol; 1999 Jan; 162(1):494-502. PubMed ID: 9886425
[TBL] [Abstract][Full Text] [Related]
10. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
[TBL] [Abstract][Full Text] [Related]
11. Interferon (IFN)-gamma , tumor necrosis factor-alpha , interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis.
Ansari NA; Ramesh V; Salotra P
J Infect Dis; 2006 Oct; 194(7):958-65. PubMed ID: 16960784
[TBL] [Abstract][Full Text] [Related]
12. Expression of TNF-alpha mRNA by peripheral blood mononuclear cells of multiple sclerosis patients treated with IFN-beta 1A.
Sarchielli P; Critelli A; Greco L; Sokola E; Floridi A; Gallai V
Cytokine; 2001 Jun; 14(5):294-8. PubMed ID: 11444910
[TBL] [Abstract][Full Text] [Related]
13. Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis.
Ysrraelit MC; Gaitán MI; Lopez AS; Correale J
Neurology; 2008 Dec; 71(24):1948-54. PubMed ID: 19064876
[TBL] [Abstract][Full Text] [Related]
14. Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis.
Link J; Söderström M; Olsson T; Höjeberg B; Ljungdahl A; Link H
Ann Neurol; 1994 Sep; 36(3):379-86. PubMed ID: 8080246
[TBL] [Abstract][Full Text] [Related]
15. T cell lymphokine-induced secretion of cytokines by monocytes from patients with multiple sclerosis.
Maimone D; Reder AT; Gregory S
Cell Immunol; 1993 Jan; 146(1):96-106. PubMed ID: 8425234
[TBL] [Abstract][Full Text] [Related]
16. Expansion of CD4+CD28- T cells producing high levels of interferon-{gamma} in peripheral blood of patients with multiple sclerosis.
Miyazaki Y; Iwabuchi K; Kikuchi S; Fukazawa T; Niino M; Hirotani M; Sasaki H; Onoé K
Mult Scler; 2008 Sep; 14(8):1044-55. PubMed ID: 18573819
[TBL] [Abstract][Full Text] [Related]
17. The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis.
Hedegaard CJ; Krakauer M; Bendtzen K; Sørensen PS; Sellebjerg F; Nielsen CH
Clin Immunol; 2008 Oct; 129(1):80-9. PubMed ID: 18653385
[TBL] [Abstract][Full Text] [Related]
18. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.
Jensen J; Krakauer M; Sellebjerg F
Cytokine; 2005 Jan; 29(1):24-30. PubMed ID: 15579375
[TBL] [Abstract][Full Text] [Related]
19. Interferon-gamma and tumor necrosis factor-alpha induce synergistic cytolytic effects in ovarian cancer cell lines-roles of the TR60 and TR80 tumor necrosis factor receptors.
Kost ER; Mutch DG; Herzog TJ
Gynecol Oncol; 1999 Mar; 72(3):392-401. PubMed ID: 10053112
[TBL] [Abstract][Full Text] [Related]
20. Impact of immunomodulatory treatment on leukocyte cytokine production in multiple sclerosis patients and healthy donors.
Reske D; Thomas AV; Petereit HF; Fink GR; Schroeter M
Neuroimmunomodulation; 2009; 16(6):385-91. PubMed ID: 19609087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
